Table 3.
Hypersusceptibility of subtype A vs. subtype D strains.
| Any | NRTI | NNRTI |
Protease inhibitor |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subtype | #Tested | ARV | ZDV | DLV | EFV | NVP | ATV | DRV/r | AMP | IDV | LPV/r | NFV | RTV | SQV | TPV/r |
| A/A1 | n = 26 | 19 | 1 | 9 | 9 | 8 | 0 | 0 | 9 | 3 | 6 | 1 | 4 | 0 | 0 |
| % | 73.1 | 3.8 | 34.6 | 34.6 | 30.8 | 0.0 | 0.0 | 34.6 | 11.5 | 23.1 | 3.8 | 15.4 | 0.0 | 0.0 | |
| D | n = 66 | 28 | 6 | 2 | 12 | 9 | 5 | 5 | 12 | 7 | 12 | 5 | 8 | 6 | 2 |
| % | 42.4 | 9.1 | 3.0 | 18.2 | 13.6 | 7.6 | 7.6 | 18.2 | 10.6 | 18.2 | 7.6 | 12.1 | 9.1 | 3.0 | |
| A vs. D* | P value | 0.01 | 0.67 | <0.001 | 0.10 | 0.07 | 0.32 | 0.32 | 0.10 | 1.00 | 0.57 | 0.67 | 0.74 | 0.18 | 1.00 |
Test results are shown for samples with evidence of hypersusceptibility to antiretroviral drugs. NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non nucleoside reverse transcriptase inhibitor. Antiretroviral drug abbreviations are defined in the legend for Table 2. In the PhenoSense HIV assay, hypersusceptibility is defined as a fold change IC50 <0.4 (indicating that replication of the test sample is inhibited by 50% at a drug level 40% of that needed for comparable inhibition of a reference strain). The table shows the number and percentage of samples with pol region HIV subtypes A/A1 or D with hypersusceptibility to each antiretroviral drug. P values are shown for comparisons between subtype A and D isolates (Fishers Exact test).